

## **Virometix appoints Dr. Pierre A. Morgon as new Chairman and Dr. Isaac Kobrin as new member of the Board of Virometix AG.**

Emmanuel Savioz nominated as new Chief Financial Officer and Prof. Paul-Henri Lambert appointed as Scientific Advisory Board member.

*Schlieren, Switzerland (25.01.2017) – Virometix today announced the appointment of Dr. Pierre A. Morgon, PharmD, LL.M., MBA as Chairman and Dr. Isaac Kobrin as independent member to its Board of Directors. In addition, the company announced the nomination of Emmanuel Savioz, MBA as new Chief Financial Officer. With these appointments Virometix is taking further steps to enhance professional expertise within the Board of Directors and senior management of the company. Furthermore, the Scientific Advisory Board has been strengthened with the addition of emeritus Prof. Paul-Henri Lambert, MD.*

**Dr. Pierre Morgon** is a doctor of pharmacy and MBA holder with additional qualifications in Business Law. He has over 30 years experience up to C-level positions in large life science companies, including Sanofi Pasteur, and biotech firms such as AJ-Biologics. In these roles, he has provided leadership in the construction and expansion of vaccine portfolios and partnerships, with turnaround initiatives and with financing for start-up vaccine companies. Dr. Morgon is also Regional Partner for Switzerland at Mérieux Développement, Non-Executive Director to the Board of Theradiag, as well as Non-Executive Director to the Board of Eurocine Vaccines.

Dr. Morgon stated: *“I am thrilled to join Virometix at a pivotal phase where we will strive to demonstrate the value of the company’s broad proprietary technology, both in the field of vaccines and in cancer immunotherapy.”*

**Dr. Isaac Kobrin**, MD is an internist with 15 years experience in academic medicine both in Israel and the USA. With 23 years of experience in the Pharma industry, he was responsible for the worldwide clinical development of key compounds at Roche for 10 years and subsequently in Actelion for 13 years. In Actelion, Dr. Kobrin was the head of clinical development and member of the executive committee for 10 years and later he was appointed as Chief Medical Officer and Chairman of the Strategic and Portfolio Board of the company. During the last 4 years, Dr. Kobrin has been supporting several Pharma and biotechnology companies as a Board member and/or as an advisor.

**Emmanuel Savioz**, MBA has 15 years experience in financing and business. He co-founded and is a Board member of several high tech companies in Switzerland including Phi Pharma, HYT, and Preciflex. Over the past 7 years, Mr. Savioz arranged more than CHF 70 million of equity financing for high tech companies in Switzerland. Previously, he worked in New York as an investment banker in M&A handling large international transactions in consumer goods and healthcare. Emmanuel Savioz is former member of the Admission Committee of the MBA Program at IMD in Lausanne, Switzerland, and holds an MBA from the Haas School of Business, University of California at Berkeley, USA.

**Prof. Paul-Henri Lambert**, MD, is now associated with the Centre of Vaccinology in the Department of Pathology and Immunology at University of Geneva. He is directing the International Advanced Course of Vaccinology (ADVAC) organized under the auspices of the Fondation Mérieux and University of Geneva. He is a member of the Governing Board of the Tuberculosis Vaccine Initiative (TBVI), past-chairman of the Human Vaccine Committee of the International Association for Biologicals (IABS) and of the Global Advisory Committee on Vaccine Safety of the World Health Organization (WHO). In 1987, he was appointed as chief of Microbiology and Immunology at the World Health Organization and in 1994, chief of the Vaccine Research and Development, WHO Global Program for Vaccines and Immunization. During this time he was deeply involved in co-ordination of research aiming at the development of vaccines against diseases of major importance in developing countries.

*“We are delighted to have some highly respected people like Dr. Morgon, Dr. Kobrin, Mr. Savioz and Prof. Lambert with their background and expertise come on board”, said Dr. Arin Ghasparian, CEO of Virometix. “They will be a perfect fit for us, as we are progressing very well with the development of our vaccine products, our scientific research and in discussions on future partnerships.”*

**For further details please contact:**

Dr. Arin Ghasparian, CEO  
[arin.ghasparian@virometix.com](mailto:arin.ghasparian@virometix.com)  
Tel: +41 43 433 86 60  
[www.virometix.com](http://www.virometix.com)

Stefan Mathys, IRF Communications AG  
[stefan.mathys@irfcom.com](mailto:stefan.mathys@irfcom.com)  
Tel : +41 43 244 81 49  
[www.irfcom.ch](http://www.irfcom.ch)

**About Virometix AG**

Virometix AG is a privately held biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and cancer. In an increasingly global world there is a considerable medical need for vaccines to combat infectious as well as a number of chronic human diseases, including cancer. Fast growing demands, health threats from newly arising complex viral and bacterial pathogens and increasingly stringent requirements for stability, safety and tolerability require new approaches to tackling current and future challenges. Rational molecular design, chemical synthesis and Virometix' proprietary "Synthetic Virus-Like Particle" platform technology allow for the rapid production and optimization of vaccine candidates with superior properties in terms of safety, efficacy and stability.

For more information about Virometix AG please visit: <http://www.virometix.com/>